NFKB1 and acute lymphoblastic leukemia: Chemotherapeutic drugs, including Ara-C, DNR, and 6-MP, trigger NF-κB activation by stimulating the ATM/TRAF6 signaling pathway, which directly upregulates bone marrow niche-protecting cytokines GDF15, CCL3, and CCL4, thereby leading to drug resistance of ALL [98].